Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient
Clin Infect Dis
.
2021 Dec 6;73(11):2144-2145.
doi: 10.1093/cid/ciab392.
Authors
Benedikt Lohr
1
,
Dirk Niemann
2
,
Jens Verheyen
3
Affiliations
1
Koblenz Laboratory, Koblenz, Germany.
2
Gemeinschaftsklinikum Mittelrhein-Ev. Stift St. Martin, Koblenz, Germany.
3
Institute of Immunology and Genetics, Kaiserslautern, Germany.
PMID:
34009286
DOI:
10.1093/cid/ciab392
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Antibodies, Neutralizing
Humans
Mutation
SARS-CoV-2*
Substances
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
bamlanivimab
Supplementary concepts
SARS-CoV-2 variants